PL2200
PL-ASA-005
Phase 2 small_molecule completed
Quick answer
PL2200 for Gastroduodenal Ulceration is a Phase 2 program (small_molecule) at Protalix BioTherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Protalix BioTherapeutics
- Indication
- Gastroduodenal Ulceration
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed